Hematologic Malignancies

Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the 2022 ASCO Annual Meeting.

Share

Program Content

Activities

  • Hematologic Malignancies Highlights: ASCO 2022
    Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2022 ASCO Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2022

    Expires: September 12, 2023

Activities

ASCEMBL 96-Wk Update
ASCEMBL: 96-Wk Update of Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2 TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

IDHENTIFY by <i>IDH2</i> Variant
Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

Pre-MEASURE: MRD in AML pre-alloHCT
Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

Crenolanib + 7+3 in AML
Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

Ponatinib/Blinatumomab in ALL
Phase II Trial of Ponatinib + Blinatumomab in Adults With Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

Magrolimab + Aza for AML
Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

Glofitamab in R/R DLBCL
Pivotal Phase II Trial of Glofitamab in R/R DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

ECHELON-1 OS Analysis
ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

ROSEWOOD
ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

Dual Anti–PD-1/Anti–LAG-3 in cHL
Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

CAPTIVATE: FD Cohort 3-Yr Update
CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

Zilovertamab + Ibr in MCL or CLL
Phase I/II Trial of Zilovertamab, an Anti-ROR1 Antibody, Plus Ibrutinib in MCL or CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

EPCORE NHL-2: DLBCL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

EPCORE NHL-2: R/R FL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R2 in R/R Follicular Lymphoma: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

ASCEND: 4-Yr Update
ASCEND: 4-Yr Follow-up Analysis of Acalabrutinib vs Rituximab + Idelalisib or Bendamustine in Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

ELEVATE-TN: 5-Yr Update
ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

ATLAS: Post-ASCT KRd
Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

GC012F Phase I
First-in-Human Study of GC012F: BCMA/CD19 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

MajesTEC-1 Update
MajesTEC-1: Update From Phase I/II Trial of the BCMA x CD3 Bispecific Antibody Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

DETERMINATION
DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

SHINE
SHINE: First-line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

Mini-HCVD + INO ± Blina in B-ALL
Mini-HyperCVD + Inotuzumab Ozogamicin ± Blinatumomab in Older Adults With Newly Diagnosed Ph-Negative B-Cell ALL: Updated Phase II Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Seagen